**MPC-7869 Clinical Rationale**

- Novel anti-amyloid treatment strategy for AD
- Selective Aβ42-Lowering Agent (SALA) in vitro & in vivo
- Inhibits amyloid fibril formation
- Reduces insoluble amyloid in mouse brain
- Improves spatial reference learning and memory performance in rats
- Effective concentrations in animal models are achievable in humans at doses that have been well tolerated
- Phase 3 trials of MPC-7869 in subjects with mild AD are ongoing

**In Vitro Inhibition of Cytochrome P450 Enzyme CYP2C9**

- Mean Tolbutamide Concentration Over Time
- Study: Single dose of tolbutamide (500 mg) given on morning of Day 1
- Samples collected for 96 hours
- 14-day washout between last dose of period 1 and first dose of period 2

**Inclusion Criteria**

- Males and females medically healthy with no clinically significant screening results
- Provided voluntarily consent to participate in the study
- Were medically healthy with no clinically significant screening results
- Had no history or current evidence of inflammatory bowel disease
- Had no history of invasive cancer within the past 5 years (excluding non-melanoma skin cancers)
- Routine use of any over-the-counter medication, including herbal supplements, within the study
- Had no history of concomitant medications or a concomitant medication was approved by the study team
- Any history or current evidence of chronic infections (hepatitis B, C, HIV, tuberculosis, or any other similar infections)
- Females without childbearing potential were
- Surgical sterilization (vasectomy) of partner at least 6 months prior to Day 1 of Period 1

**Exclusion Criteria**

- Any history or current evidence of inflammatory bowel disease
- History of invasive cancer within the past 5 years (excluding non-melanoma skin cancers)
- Routine use of any over-the-counter medication, including herbal supplements, within the study
- Any history or current evidence of chronic infections (hepatitis B, C, HIV, tuberculosis, or any other similar infections)
- Females without childbearing potential were
- Surgical sterilization (vasectomy) of partner at least 6 months prior to Day 1 of Period 1
- Any history or current evidence of chronic infections (hepatitis B, C, HIV, tuberculosis, or any other similar infections)
- Females without childbearing potential were

**Comparison of Formation Clearances**

- Tolbutamide PK Parameters
- **Effect of MPC-7869 (800 mg BID) on a Single Oral Dose of Tolbutamide: Plasma PK**
- Mean Tolbutamide Concentration Over Time
- Less than 10% difference between the resulting AUC...

**Conclusions**

- PK analysis revealed less than 10% difference between the resulting AUC...
- MPC-7869 appears safe and well-tolerated

**PDF copies of this poster are available at www.myriad.com**